Acute myeloid leukemia in the elderly: do we know who should be treated and how?

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

(2013) Jorge Cortes et al.   LANCET ONCOLOGY

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Acute myeloid leukemia in the real world: why population-based registries are needed

(2012) G. Juliusson et al.   BLOOD

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

(2012) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

(2012) Stefan Faderl et al.   CANCER

Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial

(2012) Michael S Mathisen et al.   Future Oncology

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

(2012) Stefan Faderl et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

FLT3 inhibitors in the treatment of acute myeloid leukemia

(2011) Naveen Pemmaraju et al.   CANCER

Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications

(2011) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

(2010) Fabio P. S. Santos et al.   CANCER

Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study

(2010) Cecile Pautas et al.   JOURNAL OF CLINICAL ONCOLOGY

Allografting Older Patients—Myths and Realities

(2009) Sergio Giralt   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

(2009) J.-L. Harousseau et al.   BLOOD

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

(2009) Keith Wheatley et al.   BRITISH JOURNAL OF HAEMATOLOGY

Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

(2009) Gary J. Schiller et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors

(2009) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

(2008) J. E. Karp et al.   BLOOD

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

(2008) S. Faderl et al.   BLOOD

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

(2008) J.-V. Malfuson et al.   HAEMATOLOGICA

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

(2008) Richard F. Schlenk et al.   NEW ENGLAND JOURNAL OF MEDICINE